pharmaphorum1h
J&J plots filings after psoriasis drug clears phase 3 test
Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...
pharmaphorum2h
FDA says no to Astellas' geographic atrophy drug
"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...
pharmaphorum4h
Grifols linked to €7bn takeover offer from Brookfield
Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product ...
pharmaphorum22h
AI could 'cut ECG result wait times and speed up treatment'
The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...
pharmaphorum22h
AI cuts wait times for ECG results and speeds up treatment
The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...
pharmaphorum21h
Neurogene falls again on Rett gene therapy side effects
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...